Gatifloxacin Mesylate CAS 316819-28-0injectable GMP Factory FDA Approved

• Model NO.: injection
• Use: Antibiotic
• Dosage: 2ml:200mg
• Transport Package: Box
• Specification: 2ml
• Trademark: sunbiolab
• Origin: China
• Production Capacity: 50000box

Product Description

PRODUCT NAME	Gatifloxacin Mesylate Injection
USE	INJECTION
DOSAGE	2ML:200MG;2ml:400mg
STORE	Keep out of reach of children Store below 25^oC. Protect from light

WE CAN PROVIDE CDMO(OEM) Please 

Gatifloxacin sold under the brand names Gatiflo, Tequin and Zymar, is an antibiotic of the fourth-generation fluoroquinolone family,^[1] that like other members of that family, inhibits the bacterial enzymes DNA gyrase and topoisomerase IV. Bristol-Myers Squibb introduced Gatifloxacin in 1999 under the proprietary name Tequin for the treatment of respiratory tract infections, having licensed the medication from Kyorin Pharmaceutical Company of Japan. Allergan produces it in eye-drop formulation under the names Zymar and Zymaxid. In many countries, gatifloxacin is also available as tablets and in various aqueous solutions for intravenous therapy.

Availability

Gatifloxacin is currently available in the US and Canada only as an ophthalmic solution. In China it is sold in tablet as well as in eye drop formulations.Ophthalmic anti-infectives are generally well tolerated. The concentration of the drug observed following oral administration of 400 mg gatifloxacin systemically is approximately 800 times higher than that of the 0.5% Gatifloxacin eye drop. Given as an eye drop, Gatifloxacin Ophthalmic Solution 0.3% & 0.5% cause very low systemic exposures. Therefore, the systemic exposures resulting from the gatifloxacin ophthalmic solution are not likely to pose any risk for systemic toxicities.